Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Cell Immunol. 2021 Aug 24;369:104426. doi: 10.1016/j.cellimm.2021.104426

Figure 5:

Figure 5:

Longitudinal phospho-mTOR+ MDSC cell numbers measured in the peripheral blood (whole blood) of adult, active TB disease cases. mTOR+ total MDSC cell numbers were investigated at the time of diagnosis/baseline (BL; n = 15), week two following treatment initiation (W2; n = 14), one month (M1; n = 13), two months (M2; n = 9), and six months (M6; n = 13) after treatment initiation and compared to healthy control participants (n= 4). (a) The median fluorescent intensity of phosphor-mTOR, (b) absolute cell numbers, and (c) frequency of phosphor-mTOR-expressing MDSC as a percentage of all cells (from whole blood) were assessed and determined using the FACS Canto II flow cytometer, and the third-party software FlowJo. D’Agostino & Pearson Omnibus test for normality was used to determine the distribution of the flow cytometry data, after which the statistics used were parametric (one-way ANOVA and Tukey’s multiple comparison test). Error bars represent the median and range. ***P < 0.001; **P < 0.01; *P < 0.05; ns: not significant.